Arizona State Retirement System Lowers Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Arizona State Retirement System reduced its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 7.8% in the second quarter, Holdings Channel.com reports. The firm owned 14,159 shares of the biopharmaceutical company’s stock after selling 1,201 shares during the quarter. Arizona State Retirement System’s holdings in Agios Pharmaceuticals were worth $611,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its stake in Agios Pharmaceuticals by 1.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 456,394 shares of the biopharmaceutical company’s stock worth $10,164,000 after buying an additional 4,699 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Agios Pharmaceuticals by 111.5% during the 4th quarter. BNP Paribas Financial Markets now owns 125,309 shares of the biopharmaceutical company’s stock valued at $2,791,000 after purchasing an additional 66,070 shares during the last quarter. Jump Financial LLC purchased a new position in Agios Pharmaceuticals in the 4th quarter worth $362,000. Dimensional Fund Advisors LP lifted its stake in Agios Pharmaceuticals by 5.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,596,764 shares of the biopharmaceutical company’s stock worth $57,832,000 after purchasing an additional 137,873 shares during the last quarter. Finally, Norges Bank purchased a new stake in Agios Pharmaceuticals during the fourth quarter valued at about $6,826,000.

Agios Pharmaceuticals Price Performance

AGIO stock opened at $46.69 on Monday. Agios Pharmaceuticals, Inc. has a 1 year low of $19.80 and a 1 year high of $50.35. The firm has a 50-day moving average of $45.45 and a 200 day moving average of $38.74. The company has a market cap of $2.66 billion, a P/E ratio of -7.39 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The firm had revenue of $8.60 million during the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The firm’s revenue was up 28.4% on a year-over-year basis. During the same period in the prior year, the company posted ($1.51) EPS. On average, equities research analysts expect that Agios Pharmaceuticals, Inc. will post -4.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. Royal Bank of Canada upped their price target on shares of Agios Pharmaceuticals from $53.00 to $55.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. The Goldman Sachs Group boosted their price objective on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a research report on Tuesday, June 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $51.33.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now owns 78,792 shares in the company, valued at $3,368,358. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.93% of the stock is owned by company insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.